Eric Lefkofsky’s Post

📢 Call for Papers: Cardiac SPECT 📢 We are seeking papers on Cardiac SPECT. Share your findings on its role in diagnosing and managing cardiovascular diseases. 📝 Submit your manuscript: https://imr.propub.com ⏳ Contact: [email protected] #CardiacSPECT #CardiovascularImaging #HeartDisease #CardiologyResearch #MedicalInnovation #HeartHealth Reviews in Cardiovascular Medicine

r/technology: Cardiovascular diseases identified at an early stage using machine learning and digital twins, eliminating the need for expensive diagnostic methods like MRI or CT https://lnkd.in/egRZkPRF Excited to share this article about advancements in digital twin technology.

🎗 Fostering cardio-endometriosis: a call to action for a comprehensive understanding of cardiovascular disease in endometriosis. 👉 Recently, a growing body of evidence has highlighted a concerning link between endometriosis and cardiovascular disease. Endometriosis, a chronic, inflammatory, hormone-dependent condition affecting 5–10% of reproductive-aged women worldwide, has long been associated with reproductive and gynaecological consequences. However, emerging research has suggested that it may also contribute to adverse cardiovascular outcomes. This paper aims to shed light on the importance of recognizing cardio-endometriosis as a new and developing sphere of research in the field of cardiology, thereby urging the medical community to address this pressing issue. 📚 https://lnkd.in/dEZZHdQq

Happy to share our latest work, titled "Aging-associated mechanisms of atrial fibrillation progression and their therapeutic potential", has been published in the Journal of Cardiovascular Aging. This review article was a transatlantic collaboration between Dr Xander Wehrens and fellow co-first author Shuai Zhao at the Baylor College of Medicine and the Reilly group in Oxford. In this review, we discuss the intricate link between atrial fibrillation and advancing age, the disease's major risk factor. We embed discussion of emerging therapeutic opportunities that may be able to sever the links between this immutable risk factor and the accumulation of changes that predispose the heart to atrial fibrillation. Read the full review here: https://lnkd.in/et5wt2hq

Cardiovascular diseases are the leading cause of death globally, with their prevalence increasing over recent decades. Are you paying attention to heart health and positioning your patients to achieve longevity? Gain insights in our new clinical webinar: Optimizing Cardiac Health to Live Young for a Lifetime with Dr. Jeffrey Gladden You'll learn: 🫀 The relationship between the heart’s anatomy and physiology 🫀 The advantages of using genomic, anatomic, and physiologic testing 🫀 How to manage risk with lifestyle changes based on genetics 🫀 How to combat oxidative stress for improved longevity and health span 🫀 How to recognize early warning signs of cardiac events before symptoms show Join us next Tuesday for an intricate understanding of the heart’s role in longevity and how to utilize this knowledge to enhance health and lifespan: https://hubs.ly/Q02lyBF90

Shaping the future of heart health https://lnkd.in/edNcqQ7U On World Heart Day, this collection of voices touches on the intricate relationship between type 2 diabetes and cardiovascular disease, highlights innovative treatments for rare cardiomyopathies and heart failure, and explores the potentially transformative role of artificial intelligence in cardiovascular medicine, showcasing the dedication and innovation that are shaping the future of heart health. Stephan von Haehling, MD PhD

Heart disease remains the leading cause of death for women globally, which is why at Johnson & Johnson Innovative Medicine, we recognize the urgent need to address the gaps that exist in cardiovascular research. A recent study published in the European Heart Journal revealed differences in risk factors and biological pathways related to the incidence of myocardial infarction between women and men. Research like this is a stark reminder of the need to ensure parity in recruitment of women in cardiovascular clinical trials, as they are so often underrepresented. These new data not only identify potential targets for preventative and therapeutic interventions in cardiovascular disease, but also highlight that until diverse patient populations are included in clinical trial research, we will not be able to fully address cardiovascular diseases. We cannot afford to overlook these differences any longer. Let’s work together to break down the barriers that have led to these disparities, so all receive the best care! Read more here: https://bit.ly/4eMSQcB #MyCompany #JJIMCardiopulmonary #HealthEquity

What can’t Weygovy® do?! A new study published in the Journal of the American College of Cardiology has revealed that the weight-loss drug Weygovy® can significantly lower the risk of COVID-19 deaths, heart attacks, and strokes in patients with heart disease. The trial, led by Harvard University-affiliated Brigham and Women's Hospital and funded by Novo Nordisk, the makers of #Weygovy®, was started before the COVID-19 pandemic. It found that people taking Weygovy® were just as likely to get COVID-19, but they had fewer serious illnesses or deaths related to COVID-19. The researchers do not know if the benefit of Weygovy® is due to weight loss or other effects, but suggest that extra weight may be the greatest contributor to lower life expectancy. Read more here: https://lnkd.in/en_gWHnH Find the clinical evidence for Weygovy® at DRUGDOCS®: https://lnkd.in/enuFNUqT

Can digital twins of the heart provide personalized care for heart disease patients? ❤️🩹 At the Faculty of Health, Medicine and Life Sciences (FHML), they perform a lot of research. In these Science Stories, their researchers explain their work and the tools they use to perform their research for FHML. In the Netherlands, approximately 1.7 million people suffer from cardiovascular diseases. By mapping the pumping function of the heart in detail, researchers hope to better tailor care to the patient in the future. Dr. Nick van Osta researches this by creating digital twins of the heart. In this video, he explains how a digital heart works, how it fills in the missing puzzle pieces in heart disease diagnosis and treatment and how it ultimately could be used to provide personalized care. Cardiovascular Research Institute Maastricht (CARIM) Maastricht UMC+ #ScienceStories

🌟 Check out this groundbreaking article on AI in #IschemicHeartDisease! 📚🛠️ 🔗 Read Here: https://lnkd.in/gH7ah58N #AIinHealthcare #MultimodalImaging 🚑🫀